ClinicalTrials.gg
RecruitingNCT06584032Updated Jan 7, 2025

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

A Phase 3 interventional study of fruquintinib and sintilimab in Advanced Endometrial Cancer, sponsored by Hutchmed. Recruiting at 17 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Hutchmed · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 170 studies in Endometrial Neoplasms with a site in China — 98 open to participants now, 120 under way, 21 of them phase 3. Endometrial Neoplasms · China.

Planned enrollment
30th of 140
412 · median 115
Started
2024
with 27 others
Phase 3
20 of 170
9 open now
Primary completion
2029-01
later than 103 of 119 live
Registered
116th of 170
by date

Among the 170 studies in Endometrial Neoplasms with a site in China, this one is the 30th largest by planned enrollment of the 140 interventional ones that give a count, is one of 28 that started in 2024, is one of 20 in phase 3, reaches primary completion later than 103 of the 119 other live ones, and was the 116th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

98 of the 170 studies in Endometrial Neoplasms with a site in China are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 170 studies in Endometrial Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).

Read the detailed description

A randomized, open, positive-controlled, multicenter Phase III clinical study to compare the efficacy and safety of fruquintinib(HMPL-013) plus sintilimab(IBI308) versus chemotherapy in patients with advanced endometrial cancer who have progressed after first-line standard chemotherapy

03

Conditions studied

  • Advanced Endometrial Cancer

Keywords

  • fruquintinib
  • sintilimab
  • endometrial cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have fully understood and voluntarily signed the form
  2. Age 18 to 75 years (inclusive) ; (BMI) ≥ 18.5kg/m\^2;
  3. or cytologically confirmed advanced or recurrent endometrial cancer with
  4. Patients who previously failed systemic platinum-based therapy
  5. PS (Eastern Cooperative Oncology Group performance status score) 0 or 1;
  6. Need to provide tumor samples for central lab testing of biomarkers such as MSI(microsatellite instability) status;
  7. Non-MSI-H(non-microsatellite instability-high) by central lab or previous test result indicating pMMR(proficient mismatch repair);
  8. Adequate function of the major organs;
  9. Expected survival ≥ 12 weeks;
  10. Female patients of must have a negative serum pregnancy test within 7 days before randomization.

Exclusion criteria

Exclusion Criteria:

  1. Endometrial carcinosarcoma or sarcoma;
  2. Known MMR(mismatch repair)/MSI status with dMMR(deficient mismatch repair) or MSI-H(microsatellite instability-high);
  3. Toxicities related to prior anticancer therapy did not recover to ≤ Grade 1, except alopecia and oxaliplatin-induced peripheral neurotoxicity ≤CTCAE Grade 2;
  4. Received systemic anti-tumor therapy approved within 4 weeks before randomization;
  5. Other within the past 5 years;
  6. Previous or screening central nervous system (CNS) ;
  7. Radical radiotherapy within 4 weeks before randomization
  8. Previously received any anti-programmed cell death receptor-1 () antibody, anti-PD-L1(programmed death ligand-1) antibody, anti-PD-L2(programmed death ligand-2) antibody, or anti cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody or any other antibody acting on T cell costimulation or checkpoint pathways (eg, OX40, CD137, etc) or small molecule vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors;
  9. Symptomatic or treatment-requiring thyroid dysfunction at screening;
  10. Use of agents within 4 weeks before randomization
  11. Presence of any active disease requiring systemic treatment or history of autoimmune disease within the past 2 years;
  12. Systemic immunostimulants within 4 weeks before randomization;
  13. Administration of any live or within 4 weeks before randomization or planned during the study;
  14. Major surgical procedures within 4 weeks before randomization;
  15. Uncontrolled malignant pleural effusion, ascites or pericardial effusion;
  16. Patients with current hypertension uncontrolled by medication;
  17. Patients with any current disease or condition affecting drug absorption, or patients unable to take oral medications;
  18. Receiving strong inducers of cytochrome P450 3A4 enzyme;
  19. Patients with gastrointestinal diseases or unresected tumors with active bleeding, or other conditions that may cause gastrointestinal bleeding and perforation as judged by the investigator; or with gastrointestinal perforation or gastrointestinal fistula, which is not recovered after surgical treatment;
  20. Active bleeding within 3 weeks before randomization, or melena, or bleeding from a tumor within 2 weeks before the first dose ;
  21. Tumor invading major vascular structures and is judged by the investigator to be at greater risk of massive haemorrhage;
  22. Patients who had arterial thrombosis or deep venous thrombosis within 6 months before randomization; or patients who had stroke events and/or within 12 months; patients who had thrombosis caused by implantable intravenous infusion pump or catheter, except patients who had stable thrombosis after conventional anticoagulant therapy;
  23. cardiovascular disease;
  24. Clinically significant electrolyte abnormalities as judged by the investigator;
  25. Active infection or fever of unknown origin before randomization;
  26. Patients with active pulmonary tuberculosis (TB) receiving anti-tuberculosis treatment or anti-tuberculosis treatment within 1 year before randomization;
  27. Patients with previous and current history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired pulmonary function, which may interfere with the detection and management of suspected drug-related pulmonary toxicity; previous or current (non-infectious) pulmonary inflammation requiring hormone therapy;
  28. Positive (HIV) antibody screening;
  29. Known history of clinically significant liver disease
  30. Known to any of the study drugs or any of their , or previous history of serious hypersensitivity to any other monoclonal antibody;
  31. Patients who have received other clinical drugs that have not been approved or marketed within 4 weeks before randomization;
  32. Women who are pregnant (positive pregnancy test before medication) or breastfeeding;
  33. Patients who have received tissue/organ transplantation;
  34. Patients with known psychiatric disorders or substance abuse disorders that could affect study compliance;
  35. Patients who, in the opinion of the investigator, have other reasons that would make them inappropriate for this clinical study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
412 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Patients will be treated with a planned dose of fruquintinib and sintilimab every three weeks until an IRC (independent review committee)-confirmed PD(disease progression) or meeting other discontinuation criteria.

    Drug: fruquintinib · Biological: sintilimab

  • Active comparator
    Control group

    Patients will be treated with TPC (chemotherapy of treating physician's choice, paclitaxel or doxorubicin) every three or four weeks until IRC-confirmed PD or meeting other discontinuation criteria.

    Drug: paclitaxel · Drug: doxorubicin

Interventions

  • Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.

    Also known as: HMPL-013

  • Biologicalsintilimab

    Sintilimab will be intravenously administrated on Day 1 every three weeks.

    Also known as: IBI308

  • 175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.

  • 60mg/m\^2 via IV infusion, on Day 1 every three weeks.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) as assessed by IRC

    Progression-free survival (PFS) is defined as the time from randomization to disease progression assessed by IRC or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 4 years

  2. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) , as assessed by IRC and investigator.

    Time frame: Up to approximately 4 years

  2. Duration of Response (DoR)

    For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first ,as assessed by IRC and investigator.

    Time frame: Up to approximately 4 years

  3. Disease Control Rate (DCR)

    Disease Control Rate (DCR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) or maintained a stable disease, as assessed by IRC and investigator.

    Time frame: Up to approximately 4 years

  4. Time To Response (TTR)

    Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR) ,as assessed by IRC and investigator.

    Time frame: Up to approximately 4 years

  5. Progression-Free Survival (PFS) as assessed by investigator

    Progression-Free Survival is defined as the time from randomization to disease progression assessed by investigator or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 4 years

  6. Incidence and severity of Treatment-emergent Adverse Events (TEAE)

    Adverse events classified according to NCI CTCAE version 5.0

    Time frame: Up to approximately 4 years

  7. Blood concentration of fruquintinib

    Steady-state blood concentration of fruquintinib

    Time frame: At the end of cycle 4 day 14 (each cycle is 21 days)

  8. Health-related quality of life (using EORTC QLQ-C30)

    Changes in EORTC QLQ-C30(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) scores from baseline

    Time frame: Up to approximately 4 years

  9. Health-related quality of life (using EORTC QLQ-EN24)

    Changes in EORTC QLQ-EN24 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module) scores from baseline

    Time frame: Up to approximately 4 years

07

Study locations

3 of 17 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jan 2029, 48 months after the start.

Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's planned 48 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Sep 4, 2024
StartActual
Dec 12, 2024
Primary completionEst.
Jan 8, 2029
CompletionEst.
Jun 9, 2029
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06584032
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Sep 4, 2024
Start date
Dec 12, 2024
Primary completion
Jan 8, 2029 (estimated)
Completion
Jun 9, 2029 (estimated)
Last update
Jan 7, 2025

Study contacts

Panfeng Tan
Contact
panfengt@hutch-med.com
86-21-20671828
Xiaohua Wu
principal investigator · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HMPL-013 · Sintilimab

Start the discussion